TY - JOUR T1 - Implication of exercise interventions on sleep disturbance in patients with pancreatic cancer: a study protocol for a randomised controlled trial JF - BMJ Open Gastroenterology DO - 10.1136/bmjgast-2017-000196 VL - 5 IS - 1 SP - e000196 AU - Kazunori Yoh AU - Hiroki Nishikawa AU - Hirayuki Enomoto AU - Noriko Ishii AU - Yoshinori Iwata AU - Akio Ishii AU - Yukihisa Yuri AU - Yuho Miyamoto AU - Kunihiro Hasegawa AU - Chikage Nakano AU - Ryo Takata AU - Takashi Nishimura AU - Nobuhiro Aizawa AU - Yoshiyuki Sakai AU - Naoto Ikeda AU - Tomoyuki Takashima AU - Hiroko Iijima AU - Shuhei Nishiguchi Y1 - 2018/02/01 UR - http://bmjopengastro.bmj.com//content/5/1/e000196.abstract N2 - Introduction and purpose Patients with pancreatic cancer (PC) have long been known to have high rates of depression. Depression in patients with PC can be linked to sleep disturbance. The American College of Sports Medicine notes that physical exercise is safe for most patients with cancer and physical inactivity should be avoided. However, clinical impacts of exercise interventions (EIs) on patients with PC have been poorly investigated. We aim to prospectively examine the effect of EIs on sleep disturbance in patients with PC using actigraphy, which is an objective measurement of motor activity and sleep.Methods and analysis This trial is a non-double blind randomised controlled trial. Standard therapy for each patient with PC will be allowed. When registering study subjects, a thorough assessment of the nutritional status and the daily physical activities performed will be undertaken individually for each participant. Study subjects will be randomly assigned into two groups: (1) the EI and standard therapy group or (2) the standard therapy group. In the EI and standard therapy group, physical activities equal to or higher than walking for 60 min/day will be strongly recommended. The primary outcome measure is the sleep-related variable using actigraphy (activity index) at 12 weeks.Ethics and dissemination The trial received approval from the Institutional Review Board at Hyogo College of Medicine (approval no. 2769). Final data will be publicly announced. A report releasing the study findings will be submitted for publication to an appropriate peer-reviewed journal.Trial registration number UMIN000029272; Pre-results. ER -